Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
26. September 2023 08:00 ET
|
Vaccinex, Inc.
"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer’s Disease...